Document Detail


Nutrition in oncologic patients during antiblastic treatment.
MedLine Citation:
PMID:  23276913     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cancer may induce weight loss and cachexia, and cancer treatment may contribute to nutritional impairment. Here, we review the literature on the mechanisms of cancer cachexia and the pharmacological interventions both in use in clinical practice and currently under development. Based on this analysis, several nutritional proposals for cancer patients are suggested and the importance of good nutritional status in candidates for hematopoietic stem cell transplantation is highlighted.
Authors:
Massimiliano Berretta; Mariagrazia Michieli; Raffaele Di Francia; Alessandro Cappellani; Maurizio Rupolo; Fabio Galvano; Rossella Fisichella; Salvatore Berretta; Umberto Tirelli
Related Documents :
24721833 - Synthesis and cellular characterization of novel isoxazolo- and thiazolohydrazinylidene...
21475793 - Reduced transcription of the smad4 gene during pulmonary carcinogenesis in idiopathic p...
22052623 - Role of fdg-pet as a biological marker for predicting the hypoxic status of tongue cancer.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  120-32     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Via Franco Gallini 2, 33081 Aviano (PN), Italy. mberretta@cro.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects
Cachexia / etiology,  therapy*
Complementary Therapies
Dietary Fats, Unsaturated / administration & dosage
Dietary Proteins / administration & dosage
Dietary Supplements*
Glutamine / therapeutic use
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Intestinal Mucosa / drug effects
Muscle, Skeletal / pathology
Neoplasms / therapy*
Nutritional Status*
Proteoglycans / therapeutic use
Stomatitis / drug therapy
Trametes / chemistry
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Dietary Fats, Unsaturated; 0/Dietary Proteins; 0/Proteoglycans; 56-85-9/Glutamine; 66455-27-4/krestin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Platelet-derived growth factor signaling in mesenchymal cells.
Next Document:  Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells.